echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Blood: HLA-B pilot genotype predicts hlA mismatch with prognosis of bloodless donor HCT

    Blood: HLA-B pilot genotype predicts hlA mismatch with prognosis of bloodless donor HCT

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Hematopoietic cell transplantation (HCT) from hlA mismatched non-blood-related donors can cure life-threatening blood diseases, but its success rate is limited by graft-resistant host disease (GVHD)The HLA-B pilot gene encodes methionine (M) or sucone (T) in position 2 to produce TT, MT, or MM genotypeThe dit-state HLA-B pilot gene predicts the GVHD risk of HLA-B-mismatched HCTIf the pilot gene also affects the prognosis of other HLA-mismatched transplants, the treatment strategy can be improved in the future to greatly improve the patient's prognosisPetersdorf et alidentified the pilot genotype of 11,872 patients transplanted from HLA-A,-B, -C, -DRB1 or -DQB1 non-blood donors between 1988 and 2016Using the multivariate regression method, the risk factors associated with the patient's pilot genotype were assessed according to the HLA gene base mismatch, and the risks associated with HLA-A, A,-B, -C, -DRB1 or -DQB1 were assessed based on the patient's pilot genotypeThe effectof patient's pilot genotype on acute GVHD and mortality varies depending on the HLA gene baseCompared to HLA-DQB1 mismatched TT patients, THE non-recurrence mortality rate of MM patients with HLA-DQB1 mismatches is higher (risk ratio is 1.35, p-0.01)HLA-DRB1 mismatched MM or MT patients with a higher risk of III-IV GVHD (advantage ratio 2.52 and 1.51, respectively) compared to HLA-DRB1 mismatched TT patientsPatients are more resistant to HLA-DQB1 unit mismatches than other site mismatchesThe pre-prognosis after HLA-mismatched transplantdepends on the distates of the HLA-B pilot and the HLA gene base mismatchIn summary, the limitation of the patient's pilot gene variant for HLA mismatch escticile improves new informationOr you can wisely select mismatched donors based on the patient's lead gene to increase the success rate of HLA mismatched non-blood transplants
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.